ALB and non-small cell lung carcinoma: Although albumin has previously been shown to predict survival in patients with metastatic NSCLC treated with the EGFR targeted therapy erlotinib, only 6.8% of patients had a known EGFR mutation and 90% had previous exposure to other SACT agents (27).